221 260

Cited 11 times in

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer

Authors
 Won-Ji Ryu  ;  Joo Hyuk Sohn 
Citation
 PHARMACEUTICALS, Vol.14(10) : 1008, 2021-10 
Journal Title
PHARMACEUTICALS
ISSN
 1424-8247 
Issue Date
2021-10
Keywords
heterogeneity ; molecular target ; new drugs ; triple-negative breast cancer
Abstract
Triple-negative breast cancer (TNBC) is one of the most heterogeneous diseases in solid tumors and has limited therapeutic options. Due to the lack of appropriate targetable markers, the mainstay therapeutic strategy for patients with TNBC has been chemotherapy for the last several decades. Indeed, TNBC tumors have no expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 (HER2); therefore, they do not respond to hormone therapy and HER2-targeted therapy. In this review paper, the molecular heterogeneities, possible therapeutic targets, and recently approved and upcoming drugs for TNBC will be summarized.
Files in This Item:
T202126173.pdf Download
DOI
10.3390/ph14101008
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190562
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links